Gride Ms1 Tablet 10s

Gride Ms1 Tablet 10s is an oral combination tablet containing three powerful anti-diabetic medications: Glimepiride (2mg), Metformin (1000mg), and Sitagliptin (50mg). This triple-therapy tablet is prescribed for adults with Type 2 Diabetes Mellitus whose blood sugar levels are not adequately controlled by dual therapy (often Metformin and a Sulfonylurea, or Metformin and a DPP-4 inhibitor) or who require intensified management.

The three components work synergistically to control blood glucose through complementary mechanisms:

• Glimepiride (Sulfonylurea): Stimulates the pancreas to release more insulin.

• Metformin (Biguanide): Reduces glucose production by the liver and improves the body’s sensitivity to insulin.

• Sitagliptin (DPP-4 Inhibitor): Increases insulin release and decreases liver glucose production, but only when blood sugar levels are high (glucose-dependent).

This comprehensive approach helps achieve optimal blood sugar control, reducing the risk of long-term diabetes complications like heart disease, kidney damage, and nerve problems.

Gride Ms1 Tablet 10s is a cornerstone medication used in the aggressive management of Type 2 Diabetes Mellitus that has proven resistant to conventional two-drug regimens. The triple-drug combination maximises glucose control by targeting multiple pathological defects inherent in the disease.

1. Metformin (1000mg)

Metformin is the foundation of oral diabetes treatment. It functions primarily by:

• Decreasing Hepatic Glucose Production: It lowers the amount of glucose released by the liver overnight and between meals.

• Improving Insulin Sensitivity: It enhances the uptake and utilisation of glucose by muscle cells and adipose tissue.

2. Glimepiride (2mg)

Glimepiride is a long-acting sulfonylurea. It exerts its effect by:

• Stimulating Insulin Secretion: It binds to specific receptors on the pancreatic beta cells, triggering the immediate release of preformed insulin regardless of the current glucose level.

3. Sitagliptin (50mg)

Sitagliptin is a Dipeptidyl Peptidase-4 (DPP-4) inhibitor. It works by:

• Enhancing Incretin Hormones: It blocks the DPP-4 enzyme, which normally degrades natural gut hormones called incretins (GLP-1 and GIP).

• Glucose-Dependent Action: By preserving incretins, it promotes insulin release only when blood sugar levels are high and simultaneously suppresses the liver's glucose production. This mechanism carries a lower risk of hypoglycemia compared to sulfonylureas.

The co-formulation in Gride Ms1 Tablet 10s provides a convenient, single-tablet solution that addresses insulin resistance, insufficient insulin secretion, and excessive glucose production, thereby simplifying the dosing schedule for patients requiring intensive metabolic control.

Gride Ms1 Tablet 10s (Glimepiride 2mg + Metformin 1000mg + Sitagliptin 50mg) is indicated for the following use in adults with Type 2 Diabetes Mellitus:

• Intensive Glycemic Control: To improve blood sugar control (measured by HbA1c) when diet, exercise, and therapy with two oral antidiabetic agents (e.g., Metformin and a Sulfonylurea, or Metformin and a DPP-4 inhibitor) do not provide adequate control.

• As Substitution Therapy: To replace the individual components when the patient is already taking the three drugs separately at the same dose.

The combination approach of this tablet offers several distinct therapeutic advantages in managing complex Type 2 Diabetes.

• Comprehensive Control: It simultaneously addresses the three main defects in Type 2 Diabetes: liver overproduction, insulin resistance, and pancreatic beta-cell dysfunction.

• Superior Efficacy: Triple therapy often achieves greater reductions in HbA1c than dual therapy alone.

• Dose Simplification: Combining three medications into one tablet significantly improves patient adherence and ease of use compared to taking multiple pills throughout the day.

• Targeted Action: The Sitagliptin component adds a glucose-dependent mechanism that complements the other two drugs, promoting better sugar management with a relatively lower risk of hypoglycemia than increasing the Glimepiride dose alone.

Due to the presence of three active compounds, the side effects profile reflects the risks associated with each.

Common Side Effects (Associated with Metformin):

• Gastrointestinal Distress: Nausea, vomiting, diarrhoea, abdominal pain, and metallic taste (most common upon initiation).

• Headache.

Common Side Effects (Associated with Glimepiride):

• Hypoglycemia (Low Blood Sugar): This is the most significant risk, particularly if meals are skipped or exercise is intense. Symptoms include sweating, shakiness, confusion, and rapid heartbeat.

Common Side Effects (Associated with Sitagliptin):

• Upper Respiratory Tract Infection, Nasopharyngitis.

Serious Side Effects (Seek urgent medical attention if you experience):

• Lactic Acidosis (Metformin): Rare but life-threatening complication. Symptoms include unusual muscle pain, severe tiredness, difficulty breathing, stomach pain, dizziness, and a cold feeling.

• Pancreatitis (Sitagliptin): Severe, persistent abdominal pain radiating to the back.

• Hypersensitivity/Allergic Reactions (Sitagliptin/Glimepiride): Rash, swelling of the face, tongue, or throat.

• Severe Hypoglycemia: Requires immediate sugar intake and medical help.

Gride Ms1 Tablet 10s is an oral tablet and must be taken strictly as prescribed by your doctor.

• Take with Food: The tablet should generally be taken with a meal, typically the first major meal of the day (breakfast) or as directed by the physician. Taking it with food helps minimise the common gastrointestinal side effects associated with Metformin.

• Swallow Whole: The tablet must be swallowed whole with a glass of water. Do not crush, chew, or break the tablet.

• Monitoring: Regular blood sugar monitoring, including A1c and fasting/post-meal glucose, is essential while on this medication.

• Hypoglycemia Risk: Carry a source of fast-acting sugar (e.g., glucose tablets, juice, hard candy) to treat sudden episodes of low blood sugar caused by the Glimepiride component.

• Lactic Acidosis Warning: Be aware of the signs of Lactic Acidosis: unusual muscle aches, feeling cold, extreme fatigue, difficulty breathing, stomach pain, dizziness, and a cold feeling. This is rare, but requires immediate medical help.

• Never Skip Meals: Because the Glimepiride component forces insulin release, skipping meals while on this tablet significantly increases the risk of severe hypoglycemia. Eat regular, planned meals.

• Sick Day Management: If you are severely ill, dehydrated (due to vomiting or diarrhoea), or undergoing surgery, you must stop taking this medicine temporarily and contact your doctor, as the risk of Lactic Acidosis increases.

• Pancreatitis Alert: Report any sudden, severe, or persistent stomach or back pain (possible pancreatitis) to your doctor immediately, as Sitagliptin may be a contributing factor.

• Foot Care: Continue rigorous diabetes management practices, including regular foot and eye examinations, as this medication helps manage, but does not eliminate, the risk of long-term complications.

• Store the tablets in their original blister pack at room temperature, typically below 30 °C.

• Keep the medication protected from moisture and excessive heat.

• Ensure the medication is stored out of reach and out of sight of children.

• Food: The tablet should be taken with a meal to enhance Metformin tolerability and ensure proper insulin release from Glimepiride.

• Alcohol: Strict avoidance is advised (see Safety Advice).

• Other Anti-diabetic Agents: Combining with insulin or other oral diabetes drugs requires careful dose adjustment and increased blood sugar monitoring to prevent severe hypoglycemia.

• Diuretics (Water Pills): Thiazide diuretics may worsen blood sugar control, potentially requiring an increase in the Gluconorm components.

• Corticosteroids, Thyroid Hormones, Sympathomimetics: These drugs can raise blood sugar levels, requiring close monitoring.

• Furosemide, Nifedipine, Cimetidine (Metformin): Can interfere with Metformin's clearance, increasing the risk of Lactic Acidosis.

This triple combination is contraindicated or requires extreme caution in patients with:

• Severe Renal Impairment (Kidney Disease): Risk of Metformin accumulation and Lactic Acidosis.

• Metabolic Acidosis (Including Diabetic Ketoacidosis): Contraindication.

• Cardiovascular Collapse (Shock) or Acute Heart Failure: Conditions associated with hypoxemia increase the risk of Lactic Acidosis.

• Pancreatitis History: Caution is advised due to the Sitagliptin component.

• G6PD Deficiency: Glimepiride (Sulfonylurea) may cause haemolytic anaemia in patients with this deficiency.

The standard dose is one tablet (Glimepiride 2mg + Metformin 1000mg + Sitagliptin 50mg) once daily with a meal.

The dose is fixed for this strength, but the physician may adjust the strength or prescribe additional medications based on the patient's target blood glucose goals and response to therapy.

An overdose is highly dangerous, primarily due to the severe risk of hypoglycemia from Glimepiride and the risk of Lactic Acidosis from Metformin.

• Symptoms: Signs of severe hypoglycemia (unconsciousness, seizures) or Lactic Acidosis (severe nausea/vomiting, deep/rapid breathing).

• Action: If an overdose is suspected, seek emergency medical care immediately. Immediate treatment for severe hypoglycemia (IV glucose) and management of Lactic Acidosis (often requiring hospitalisation) are necessary.

If you miss a dose of Gride Ms1 Tablet 10s :

• Take the missed dose as soon as you remember, IF it is still close to your scheduled mealtime.

• If you remember close to your next dose or meal, skip the missed dose and continue with your regular schedule.

• Do not take two doses at the same time to make up for a missed one, as this greatly increases the risk of hypoglycemia and side effects.